Literature DB >> 27951579

Evidence for the Clinical Advantages of Predilution On-Line Hemodiafiltration.

Ikuto Masakane, Kan Kikuchi, Hideki Kawanishi.   

Abstract

BACKGROUND: On-line hemodiafiltration (OL-HDF) is a rapidly developing dialysis modality that is expected to ameliorate the quality of life and survival rate of chronic dialysis patients. There are generally 2 types of dilution methods in OL-HDF: postdilution and predilution.
SUMMARY: Postdilution OL-HDF is widely performed worldwide, whereas predilution OL-HDF accounts for >90% of all OL-HDF sessions performed in Japan. The reasons for the preference for predilution are to increase the substitution volume at a lower blood flow rate and to remove larger low-molecular-weight proteins (LMWPs). It is a unique Japanese concept for chronic dialysis to remove larger LMWPs, in so-called 'protein permeable dialysis', and ameliorate various uremic symptoms. Evidence for the beneficial effects of OL-HDF has not yet been confirmed, especially in the case of the predilution mode. The beneficial effects of predilution OL-HDF have recently been evaluated by 2 Japanese studies. A study by the Japanese Society for Dialysis Therapy (JSDT) found a clear survival benefit for all-cause mortality and cardiovascular mortality of predilution OL-HDF with a substitution volume >40 liters/session. A study by the Japanese Society for Hemodiafiltration (JSHDF) showed the noninferiority of predilution OL-HDF in relation to intradialytic hemodynamic stability compared with the postdilution mode. Key Messages: Further analysis of the JSDT and JSHDF studies may confirm the superiority of predilution OL-HDF over high-flux or super high-flux hemodialysis.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 27951579     DOI: 10.1159/000450635

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  8 in total

1.  Semi-Quantitative Evaluation of Asymmetricity of Dialysis Membrane Using Forward and Backward Ultrafiltration.

Authors:  Akihiro C Yamashita; Toshiki Kakee; Takahisa Ono; Jun Motegi; Satoru Yamaguchi; Takashi Sunohara
Journal:  Membranes (Basel)       Date:  2022-06-15

2.  Assessment of removal and adsorption enhancement of high-flux hemodialyzers in convective therapies by a novel in vitro uremic matrix.

Authors:  Miquel Gomez; Elisenda Bañon-Maneus; Marta Arias-Guillén; Francisco Maduell
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

Review 3.  Significance of Levocarnitine Treatment in Dialysis Patients.

Authors:  Hiroyuki Takashima; Takashi Maruyama; Masanori Abe
Journal:  Nutrients       Date:  2021-04-07       Impact factor: 5.717

Review 4.  High-volume online haemodiafiltration treatment and outcome of end-stage renal disease patients: more than one mode.

Authors:  Helmut Schiffl
Journal:  Int Urol Nephrol       Date:  2020-06-02       Impact factor: 2.370

Review 5.  Current approaches to middle molecule removal: room for innovation.

Authors:  Ikuto Masakane; Kenji Sakurai
Journal:  Nephrol Dial Transplant       Date:  2018-10-01       Impact factor: 5.992

Review 6.  Clinical evidence on haemodiafiltration.

Authors:  Peter J Blankestijn; Muriel P Grooteman; Menso J Nube; Michiel L Bots
Journal:  Nephrol Dial Transplant       Date:  2018-10-01       Impact factor: 5.992

7.  Removal of large middle molecules via haemodialysis with medium cut-off membranes at lower blood flow rates: an observational prospective study.

Authors:  Tae Hoon Kim; Seok-Hyung Kim; Tae Yeon Kim; Hae Yeul Park; Kwon Soo Jung; Moon Hyoung Lee; Jong Hyun Jhee; Jung Eun Lee; Hoon Young Choi; Hyeong Cheon Park
Journal:  BMC Nephrol       Date:  2019-12-31       Impact factor: 2.388

8.  Enhancement of solute clearance using pulsatile push-pull dialysate flow for the Quanta SC+: A novel clinic-to-home haemodialysis system.

Authors:  Clive Buckberry; Nicholas Hoenich; Detlef Krieter; Horst-Dieter Lemke; Marieke Rüth; John E Milad
Journal:  PLoS One       Date:  2020-03-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.